Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2026 14:00 ET | Source: MannKind

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent...
May 29, 2026 12:30 ET | Source: MannKind

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

MannKind Announces FDA Approval of Afrezza® the 1st & Only Inhaled Mealtime Insulin for Use in Children & Adolescents Aged 6 and Older Living with Diabetes
May 28, 2026 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies...
May 28, 2026 03:30 ET | Source: ViCentra

ViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit Economics

ViCentra triples Kaleido manufacturing capacity via Phillips Medisize partnership, enabling patch pump supply for 17,000+ users across European markets.
May 27, 2026 09:05 ET | Source: MannKind

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

MANNKIND TO SHOWCASE NEW DATA AT ADA 2026 ADVANCING UNDERSTANDING OF INHALED INSULIN (AFREZZA®) IN PEDIATRIC CARE, PREGNANCY AND USE WITH AID SYSTEMS
May 27, 2026 07:55 ET | Source: NewcelX Ltd.

NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes

Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”;...
May 21, 2026 07:30 ET | Source: Antag Therapeutics

Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer

Copenhagen, Denmark, 21 May 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces the appointment...
May 12, 2026 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C....
May 06, 2026 13:17 ET | Source: AliveCor Inc.

Diathrive Health and KardiaComplete Announce Strategic Partnership to Address Cardiometabolic Risk

Diathrive Health and AliveCor announced partnership to deliver a more comprehensive approach to cardiometabolic care for employers
April 23, 2026 09:00 ET | Source: Heald

Heald Partners with Thatch Marketplace to Bring First-of-its-Kind Diabetes Reversal Program to Employees

ALPHARETTA, Ga., April 23, 2026 (GLOBE NEWSWIRE) -- Heald, a leader in digital-first diabetes reversal, today announced a new partnership with Thatch, the modern health benefits platform. Through...